0 Items
Select Page

Trichomoniasis

Trichomoniasis is a sexually transmitted infection (STI) caused by a parasite called Trichomonas vaginalis (TV), that causes an estimated 5 million new cases in the US each year.

The Native Antigen Company prepares Trichomonas antigens in cell culture, for use in immunoassay development.

Trichomonas Background

Trichomonas vaginalis is a flagellated parasitic protozoan, belonging to the Trichomonadidae family of parasites. Trichomonas is the causative agent of the sexually transmitted disease known as Trichomoniasis. Morphologically, Trichomonas exists as a trophozoite and cannot survive for long periods in the external environment. It is an obligate parasite that infects both men and women. The parasite infects the squamous epithelium of the genital tract, and replicates in the lower genital tract of women and the urethra and prostate of men (Kissinger, P).

In humans, Trichomonas is transmitted through skin-to skin contact, usually during sexual activity. Trichomonas infection is reported to be the most common, non-viral, sexually transmitted infection (STI) in the world. The prevalence of Trichomonas infection varies from country to country, but over 11% of women are thought to be affected worldwide. However, the Trichomonas is not a reportable disease and therefore the incidence of Trichomonas infection is likely higher. Studies also suggest that Trichomonas infection is associated with an increased risk of developing other STIs, including human immunodeficiency virus (HIV).

In both men and women, Trichomonas is typically asymptomatic. However, a third of asymptomatic cases in women can become symptomatic over a period of 6 months. Symptoms of Trichomonas infection include vaginal discharge, dysuria, itching, vulvar discharge and abdominal pain. Trichomonas infection has also been associated with pelvic inflammatory disease, low birth rate and preterm delivery. In men, Trichomonas infection can cause epididymitis, prostatitis and decreased sperm motility (CDC).

Improvements in diagnostic testing for Trichomonas may reveal a higher incidence of Trichomonas infection, which given the association with an increased risk of developing other STIs, is a significant cause for concern in the global health community.

References

  1. Kissinger P. 2015. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.BMC Infect Dis. Aug 5;15:307.
  1. Centers for Disease Control and Prevention: Trichomoniasis

 

Trichomonas Antigens

We offer washed, lysed and purified Trichomonas vaginalis protozoa, prepared in carefully controlled conditions. These Trichomonas antigens are suitable for use in IVD kit manufacture or research.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

9 + 11 =

Live Customer Feedback

Join our mailing list

* indicates required